China De Xiao Quan Care Group Co., Ltd (CDXQ) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.01 means the share price is 0.01 times one year of earnings per share.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerChina De Xiao Quan Care Group Co., Ltd (CDXQ) trades at $0.0004. China De Xiao Quan Care Group Co., Ltd. is a shell company with no significant operations, formerly involved in the medical marijuana sector. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for CDXQ: CDXQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
China De Xiao Quan Care Group Co., Ltd (CDXQ) Healthcare & Pipeline Overview
China De Xiao Quan Care Group Co., Ltd., based in New York, operates as a shell company, previously exploring medical marijuana technologies. With minimal operations and a small team, the company's current market position is tenuous, reflecting the high-risk nature of shell corporations within the financial services sector.
What Is the Investment Thesis for CDXQ?
Investing in China De Xiao Quan Care Group Co., Ltd. presents substantial risks due to its status as a shell company with no significant operations. The company's negative beta of -45.33 indicates an inverse correlation with the market, which is not necessarily indicative of stability. With a market cap of $0.00B and no dividend yield, the company offers no immediate return on investment. Any potential value would depend on speculative future activities, such as a reverse merger or acquisition. Investors may want to evaluate the high degree of uncertainty and the potential for complete loss of investment. The absence of revenue and active business operations makes traditional valuation methods inapplicable.
Based on FMP financials and quantitative analysis
CDXQ Key Highlights
Market capitalization of $0.00B, reflecting the company's lack of significant operations.
- P/E ratio of 0.01, indicative of minimal earnings relative to its market capitalization.
- Beta of -45.33, suggesting an inverse correlation with the market.
- No dividend yield, indicating no current income for investors.
- Operates as a shell company with no significant ongoing business activities.
Who Are CDXQ's Competitors?
CDXQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | 33 5-pillar |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | 39 5-pillar |
| PETS PetMed Express, Inc. | $1.33 | -2.21% | $28.4M | 32 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CDXQ's Key Strengths?
Publicly listed status provides potential access to capital markets.
- Existing corporate structure facilitates potential restructuring or acquisition.
- Previous experience in the medical marijuana market provides some industry knowledge.
- Low operating costs due to minimal activity.
What Are CDXQ's Weaknesses?
Lack of significant operations and revenue generation.
- Dependence on speculative future activities.
- Limited assets and resources.
- Negative market perception due to shell company status.
What Are the Key Risks for CDXQ?
Negative return on equity (-45.5%) — the business is not currently generating profit on shareholder capital.
- Regulatory scrutiny and delisting from the OTC market.
- Inability to attract suitable acquisition or merger partners.
- Failure to identify a viable new business model.
- Limited financial resources and dependence on external funding.
- Negative market perception due to shell company status.
What Are CDXQ's Competitive Advantages?
- As a shell company, China De Xiao Quan Care Group Co., Ltd. has no discernible competitive advantages.
- Its publicly listed status could provide a slight advantage in terms of access to capital markets, but this is not a significant moat.
- Any future competitive advantages will depend on the company's strategic direction and ability to execute.
What Does CDXQ Do?
China De Xiao Quan Care Group Co., Ltd., incorporated in 2012 and based in New York, currently lacks significant operational activities. Historically, the company focused on the development and commercialization of technologies within the medical marijuana market under its former name, Nhale, Inc. However, it has since ceased these activities. As of 2026, the company's primary function appears to be that of a shell corporation, with minimal assets or ongoing business operations. The company's transition from the medical marijuana sector to its current state reflects a significant shift in its strategic direction, leaving it without a clear market focus or revenue-generating activities. With a single employee and a market capitalization of $0.00B, the company's financial footprint is negligible. The company's future prospects are uncertain, dependent on potential restructuring or acquisition opportunities. The company's competitive positioning is non-existent, given its lack of active operations and market presence.
What Products and Services Does CDXQ Offer?
- Currently, China De Xiao Quan Care Group Co., Ltd. functions as a shell company.
- Previously, the company was involved in the development of medical marijuana technologies.
- The company seeks potential opportunities for restructuring or acquisition.
- It maintains a corporate structure as a publicly listed entity.
- The company explores options for future business ventures.
- It manages its limited assets and corporate obligations.
How Does CDXQ Make Money?
- Currently, the company does not have an active business model.
- Historically, the company aimed to generate revenue through the commercialization of medical marijuana technologies.
- Future revenue generation is contingent on potential restructuring or acquisition opportunities.
What Industry Does CDXQ Operate In?
China De Xiao Quan Care Group Co., Ltd. operates within the shell company segment of the financial services industry. Shell companies are often characterized by minimal operations and are sometimes used for reverse mergers or acquisitions. The industry is highly speculative and carries significant risks due to the lack of transparency and operational activity. Regulatory scrutiny is high, and the success of such entities depends heavily on future strategic decisions and market conditions. The competitive landscape is difficult to define, as shell companies are not directly competing in traditional markets but rather seeking opportunities for restructuring or acquisition.
Who Are CDXQ's Key Customers?
- Currently, the company does not have any active customers.
- Historically, the company targeted patients and consumers in the medical marijuana market.
- Future customer base will depend on the company's strategic direction.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
China De Xiao Quan Care Group Co., Ltd operates in the Healthcare sector. It is headquartered in Nanjing, CN. The company is led by CEO Chunsheng Qin. CDXQ has traded publicly since 2013.
Key Financial Metrics
Return on equity for China De Xiao Quan Care Group Co., Ltd stands at -45.5%, a gauge of how efficiently it converts shareholder capital into profit. CDXQ trades at a trailing price-to-earnings ratio of 0.01, below the Financial Services sector average of ~17.20x.
Financial Health
China De Xiao Quan Care Group Co., Ltd's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
CDXQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
CDXQ Latest News
No recent news available for CDXQ.
CDXQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CDXQ.
Price Targets
Wall Street price target analysis for CDXQ.
CDXQ MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CDXQ; grades run from A+ (80-100) to F (below 30).
Leadership: Chunsheng Qin
Managing
Chunsheng Qin serves as the managing person for China De Xiao Quan Care Group Co., Ltd. Information regarding Mr. As the company currently operates with only one employee, Mr. Qin's role likely encompasses a broad range of administrative and strategic responsibilities. His background and expertise are critical to guiding the company through its current period of transition and exploring potential future opportunities.
Track Record: Given the company's current state as a shell corporation with minimal operations, it is difficult to assess Mr. Qin's track record. His primary focus has likely been on maintaining the company's corporate structure and exploring potential strategic options. Any future success will depend on his ability to identify and execute a viable business plan.
CDXQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that China De Xiao Quan Care Group Co., Ltd. may not meet the minimum financial standards or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier often have limited trading volume and liquidity, and may be subject to greater regulatory scrutiny. Investing in OTC Other stocks carries significant risks due to the lack of transparency and the potential for fraud or manipulation. Compared to NYSE/NASDAQ, OTC markets have far less stringent listing requirements.
- OTC Tier: OTC Other
- Limited or no financial disclosure increases the risk of investing due to lack of transparency.
- Low trading volume and liquidity can lead to significant price volatility.
- Potential for fraud or manipulation is higher on the OTC Other tier.
- Company's status as a shell corporation increases the risk of complete loss of investment.
- Dependence on speculative future activities makes the investment highly uncertain.
- Verify the company's legal status and regulatory compliance.
- Obtain and review any available financial statements.
- Assess the company's management team and their track record.
- Evaluate the company's potential for future growth or restructuring.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a financial advisor before making any investment decisions.
- Check for any history of regulatory actions or legal issues.
- Publicly listed status provides some level of regulatory oversight.
- Company has been incorporated since 2012.
- Presence of a management team, however small.
- Company maintains a registered office in New York.
Common Questions About CDXQ (Healthcare)
What does China De Xiao Quan Care Group Co., Ltd do?
China De Xiao Quan Care Group Co., Ltd. currently operates as a shell company, meaning it has no significant ongoing business operations.
What do analysts say about CDXQ stock?
There is currently no analyst coverage for China De Xiao Quan Care Group Co., Ltd. due to its status as a shell company with minimal operations. Investors should conduct thorough due diligence and consider the high degree of uncertainty before investing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is limited due to the company's status as a shell corporation.
- Financial data may not be reliable or up-to-date.
- Future prospects are highly speculative and uncertain.